| Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin αvβ3 S Lakshmikanthan, M Sobczak, C Chun, A Henschel, J Dargatz, ... Blood, The Journal of the American Society of Hematology 118 (7), 2015-2026, 2011 | 120 | 2011 |
| Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure S Lakshmikanthan, BJ Zieba, ZD Ge, K Momotani, X Zheng, H Lund, ... Arteriosclerosis, thrombosis, and vascular biology 34 (7), 1486-1494, 2014 | 61 | 2014 |
| The small GTPase Rap1b negatively regulates neutrophil chemotaxis and transcellular diapedesis by inhibiting Akt activation S Kumar, J Xu, RS Kumar, S Lakshmikanthan, R Kapur, M Kofron, ... Journal of Experimental Medicine 211 (9), 1741-1758, 2014 | 59 | 2014 |
| Sphingosine-1-phosphate receptor 1 activity promotes tumor growth by amplifying VEGF-VEGFR2 angiogenic signaling VAB Ragunathrao, M Anwar, MZ Akhter, A Chavez, V Natarajan, ... Cell reports 29 (11), 3472-3487. e4, 2019 | 54 | 2019 |
| Rap1 promotes endothelial mechanosensing complex formation, NO release and normal endothelial function S Lakshmikanthan, X Zheng, Y Nishijima, M Sobczak, A Szabo, ... EMBO reports 16 (5), 628-637, 2015 | 48 | 2015 |
| Rap1B promotes VEGF-induced endothelial permeability and is required for dynamic regulation of the endothelial barrier S Lakshmikanthan, M Sobczak, S Li Calzi, L Shaw, MB Grant, ... Journal of cell science 131 (1), jcs207605, 2018 | 45 | 2018 |
| Endothelial Rap1 (Ras-association proximate 1) restricts inflammatory signaling to protect from the progression of atherosclerosis B Singh, R Kosuru, S Lakshmikanthan, MG Sorci-Thomas, DX Zhang, ... Arteriosclerosis, thrombosis, and vascular biology 41 (2), 638-650, 2021 | 27 | 2021 |
| Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing JA Barrett, J Choi, S Lakshmikanthan, YY Kim, D Greene, P Kolli, ... Experimental Hematology 92, 51-61, 2020 | 11 | 2020 |
| Rap1b-loss increases neutrophil lactate dehydrogenase activity to enhance neutrophil migration and acute inflammation in vivo CS Chowdhury, E Wareham, J Xu, S Kumar, M Kofron, S Lakshmikanthan, ... Frontiers in immunology 13, 1061544, 2022 | 4 | 2022 |
| Endothelial Rap1B mediates T-cell exclusion to promote tumor growth: a novel mechanism underlying vascular immunosuppression GP Sharma, R Kosuru, S Lakshmikanthan, S Zheng, Y Chen, R Burns, ... Angiogenesis 26 (2), 265-278, 2023 | 2 | 2023 |
| Distinct signaling functions of Rap1 isoforms in NO release from endothelium R Kosuru, B Singh, S Lakshmikanthan, Y Nishijima, J Vasquez-Vivar, ... Frontiers in Cell and Developmental Biology 9, 687598, 2021 | 2 | 2021 |
| Justification for a Fixed Dose of Eflapegrastim, a Long‐Acting G‐CSF, in Patients Receiving Docetaxel‐Cyclophosphamide Chemotherapy JA Barrett, D Greene, S Lakshmikanthan, P Kolli, S Chawla, F Lebel The Journal of Clinical Pharmacology 61 (2), 204-210, 2021 | 2 | 2021 |
| Novel tetravalent bispecific T-cell engaging antibodies for cancer immunotherapy S Lakshmikanthan, T Wyant, S Pandian, S Murphy, Y Chen Journal Clinical Oncology 37 (suppl; abstr e12513), 2019 | 2 | 2019 |
| Adhesion 495 nicka, Rap1 promotes VEGFR2 activation and angio-genesis by a mechanism involving integrin avb3 S Lakshmikanthan, M Sobczak, C Chun, A Henschel, J Dargatz, ... Blood 118, 20152026, 2011 | 2 | 2011 |
| Intratumoral delivery of mPH-804 (TIGIT targeting INTASYL compound) inhibits tumor growth and confers an inflammatory tumor microenvironment S Lakshmikanthan, A Jedinak, M Maxwell, M Kadiyala, D Yan, J Cardia, ... AACR Annual Meeting, 2020 | 1 | 2020 |
| Methods for promoting anti-tumor immune response in a subject in need thereof using encapsulated interleukin 12 S Lakshmikanthan, P Kolli, F Lebel, JA Barrett US Patent App. 18/177,787, 2023 | | 2023 |
| Intratumorally administrated encapsulated IL-12 (PCX12) promotes anti-tumor immune response in GL-261 murine orthotopic glioma model S Lakshmikanthan, D Diaz, P Kolli, A Thiagalingam, PM Gonzales, ... Cancer Research 82 (12_Supplement), 2086-2086, 2022 | | 2022 |
| Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations A Thiagalingam, S Lakshmikanthan, AJ Mak, SA Shell, S Leu, ... Cancer Research 82 (12_Supplement), 3400-3400, 2022 | | 2022 |
| Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib. A Thiagalingam, S Lakshmikanthan, A Mak, SA Shell, S Leu, S Sun, ... Journal of Clinical Oncology 40 (16_suppl), 3051-3051, 2022 | | 2022 |
| Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex JA Barrett, S Lakshmikanthan US Patent App. 17/374,302, 2022 | | 2022 |
Sachin KumarSenior Scientist, CSIR-CDRI, Lucknow, India-226031Verified email at cchmc.org
